Foghorn Therapeutics Reports Q1 2026 Financial Results with $3.3M Revenue and $19.9M Net Loss

Foghorn Therapeutics Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $3.3 million, a decrease from $6.0 million in the same period last year. The decline in revenue is attributed to the timing of work performed under the company's collaboration agreement with Eli Lilly and Company. The company incurred a net loss of $19.9 million for the quarter, slightly higher than the $18.8 million loss reported in the first quarter of 2025. The loss per share attributable to common stockholders was $(0.29), compared to $(0.30) in the prior year.

Total operating expenses for the quarter were $24.8 million, down from $28.9 million in the previous year, primarily due to reduced research and development costs, which fell to $18.3 million from $21.6 million. This decrease was driven by lower expenses related to partnered programs with Lilly and a reduction in costs associated with the discontinued development of FHD-286. General and administrative expenses also decreased to $6.6 million from $7.2 million, reflecting lower facility and IT-related costs.

Foghorn's cash, cash equivalents, and marketable securities totaled $183.6 million as of March 31, 2026, an increase from $166.9 million at the end of 2025. The company raised approximately $50 million in gross proceeds from a direct offering of common stock and warrants in January 2026, which contributed to the increase in cash reserves. The company continues to rely on funding from equity offerings and collaborations to support its operations, as it has not yet generated revenue from product sales.

In terms of operational developments, Foghorn is advancing its clinical-stage drug candidate, FHD-909, which is currently in a Phase 1 dose escalation study. The company has also transitioned the development of FHD-909 to Lilly, which will lead the clinical development while Foghorn shares in the costs. As of March 31, 2026, Foghorn had an accumulated deficit of $652.3 million and expects to continue incurring significant operating losses in the foreseeable future.

Looking ahead, Foghorn anticipates that its expenses will increase as it continues to advance its clinical programs and expand its research activities. The company is focused on leveraging its Gene Traffic Control platform to develop new oncology medicines and is actively seeking additional funding to support its growth strategy. Foghorn's management has indicated that while they expect their current cash reserves to be sufficient for at least the next 12 months, they will need to secure additional financing to sustain their operations and development efforts.